MedPath

MedImmune LLC

MedImmune LLC logo
๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
Subsidiary
Established
1987-01-01
Employees
5K
Market Cap
-
Website
http://medimmune.com

Study of the Efficacy and Safety of MEDI4893

Phase 2
Completed
Conditions
Staphylococcus Aureus Pneumonia
Interventions
Other: Placebo
First Posted Date
2014-11-20
Last Posted Date
2019-12-23
Lead Sponsor
MedImmune LLC
Target Recruit Count
213
Registration Number
NCT02296320
Locations
๐Ÿ‡จ๐Ÿ‡ญ

Research Site, Lausanne, Switzerland

A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants

Phase 1
Completed
Conditions
Respiratory Syncytial Virus
Interventions
Drug: MEDI8897 10 mg
Drug: Placebo
Drug: MEDI8897 25 mg
Drug: MEDI8897 50 mg
First Posted Date
2014-11-14
Last Posted Date
2018-09-19
Lead Sponsor
MedImmune LLC
Target Recruit Count
151
Registration Number
NCT02290340
Locations
๐Ÿ‡ฟ๐Ÿ‡ฆ

Research Site, Pretoria, South Africa

A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults

Phase 1
Completed
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Biological: MEDI7510
Biological: IIV
First Posted Date
2014-11-13
Last Posted Date
2018-03-15
Lead Sponsor
MedImmune LLC
Target Recruit Count
363
Registration Number
NCT02289820
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Research Site, Nashville, Tennessee, United States

Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis

Phase 1
Completed
Conditions
Rheumatoid Arthritis
Interventions
Other: Placebo
Biological: AMP-110
First Posted Date
2014-10-29
Last Posted Date
2016-11-21
Lead Sponsor
MedImmune LLC
Target Recruit Count
29
Registration Number
NCT02277574
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Physician Research Collaboration, LLC, Lincoln, Nebraska, United States

๐Ÿ‡บ๐Ÿ‡ธ

Metroplex Clinical Research Center, Dallas, Texas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Pinnacle Research Group, LLC, Anniston, Alabama, United States

and more 4 locations

Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

Phase 1
Completed
Conditions
Relapsed/Refractory Aggressive B-cell Lymphomas
Interventions
First Posted Date
2014-10-22
Last Posted Date
2018-03-12
Lead Sponsor
MedImmune LLC
Target Recruit Count
10
Registration Number
NCT02271945
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Research Site, Milwaukee, Wisconsin, United States

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

Phase 1
Completed
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Biological: MEDI4736
Biological: tremelimumab
First Posted Date
2014-10-13
Last Posted Date
2017-10-23
Lead Sponsor
MedImmune LLC
Target Recruit Count
71
Registration Number
NCT02262741
Locations
๐Ÿ‡จ๐Ÿ‡ฆ

Research Site, Toronto, Ontario, Canada

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
Biological: MEDI4736
Biological: tremelimumab
First Posted Date
2014-10-10
Last Posted Date
2020-03-06
Lead Sponsor
MedImmune LLC
Target Recruit Count
380
Registration Number
NCT02261220
Locations
๐Ÿ‡ฌ๐Ÿ‡ง

Research Site, Wirral, United Kingdom

Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults

Phase 1
Completed
Conditions
MEDI3902 for Prevention of P. Aeruginosa Pneumonia
Interventions
Drug: MEDI3902 - Dose 3
Drug: MEDI3902 - Dose 4
Other: Placebo
Drug: MEDI3902 - Dose 1
Drug: MEDI3902 - Dose 2
First Posted Date
2014-10-03
Last Posted Date
2018-08-13
Lead Sponsor
MedImmune LLC
Target Recruit Count
56
Registration Number
NCT02255760
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Research Site, South Miami, Florida, United States

Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma

Phase 2
Terminated
Conditions
B-Cell Pediatric ALL
Interventions
First Posted Date
2014-08-27
Last Posted Date
2017-04-06
Lead Sponsor
MedImmune LLC
Target Recruit Count
37
Registration Number
NCT02227108
Locations
๐Ÿ‡ฌ๐Ÿ‡ง

Research Site, Bristol, United Kingdom

A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

Phase 1
Completed
Conditions
Recurrent or Metastatic Solid Tumors
Interventions
Biological: MEDI6383 and MEDI4736
Biological: MEDI6383
First Posted Date
2014-08-21
Last Posted Date
2019-03-13
Lead Sponsor
MedImmune LLC
Target Recruit Count
39
Registration Number
NCT02221960
Locations
๐Ÿ‡ฆ๐Ÿ‡บ

Research Site, Parkville, Australia

ยฉ Copyright 2025. All Rights Reserved by MedPath